This Vaccine Maker May Be Next to Go After the Kids’ Market

1 min read

Right now, most people rolling up their sleeves for an authorized coronavirus vaccine are adults. The U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) to Moderna (NASDAQ: MRNA) and Johnson & Johnson vaccines for people age 18 and older. Only Pfizer (NYSE: PFE) has the right to use its vaccine in some minors — those age 16 and older. That’s due to the age of volunteers Pfizer recruited in its trials.

But soon the FDA may authorize a vaccine for more teens and younger children. Last month, Moderna and Pfizer both announced the start of clinical trials in kids ages six months through 11 years old. Both already had started teen trials.

Now, a third company is about to try for this billion-dollar market.

Continue reading

Leave a Reply

Your email address will not be published.

Previous Story

Could Roblox Be a Millionaire-Maker Stock?

Next Story

3 Unstoppable Growth Trends to Invest in Today

Latest from Blog